Ambrisentan for the Treatment of Pulmonary Arterial Hypertension Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy
نویسندگان
چکیده
Nazzareno Galiè, MD; Horst Olschewski, MD; Ronald J. Oudiz, MD; Fernando Torres, MD; Adaani Frost, MD; Hossein A. Ghofrani, MD; David B. Badesch, MD; Michael D. McGoon, MD; Vallerie V. McLaughlin, MD; Ellen B. Roecker, PhD; Michael J. Gerber, MD; Christopher Dufton, PhD; Brian L. Wiens, PhD; Lewis J. Rubin, MD; for the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group
منابع مشابه
Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.
BACKGROUND This study evaluated long-term outcomes in patients with pulmonary arterial hypertension (PAH) undergoing treatment with ambrisentan monotherapy, a selective oral endothelin-1 receptor antagonist. METHODS AND RESULTS Patients who participated in the Ambrisentan in Pulmonary Arterial Hypertension: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy Study (AR...
متن کاملLong-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
OBJECTIVES This study evaluated the safety and efficacy of ambrisentan for a period of 2 years in patients with pulmonary arterial hypertension (PAH). BACKGROUND Ambrisentan is an oral, once-daily endothelin receptor antagonist that is selective for the endothelin type A receptor. The ARIES-1 (Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multic...
متن کاملTreatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
BACKGROUND Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung fibroblast proliferation and contractile activity via the endothelin A (ETA) receptor. OBJECTIVE To determine whether ambrisentan, an ETA receptor-selective antagonist, reduces the rate of IPF progression. DESIGN Randomized, double-blind, placebo-contr...
متن کاملAmbrisentan therapy for pulmonary arterial hypertension.
OBJECTIVES The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan, an oral endothelin type A receptor-selective antagonist, in patients with pulmonary arterial hypertension (PAH). BACKGROUND Pulmonary arterial hypertension is a life-threatening and progressive disease with limited treatment options. Endothelin is a vasoconstrictor and smooth muscle cell ...
متن کاملPulmonary Arterial Hypertension: Role of Ambrisentan
Increasing numbers of experimental investigations and recently also of clinical trials strongly suggest an integral involvement of the endothelin (ET) system in the pathophysiology of a variety of disease states, mainly of the cardiovascular system.Ambrisentan (LU 208075)approved by the US Food and Drug Administration in 2007, a selective ETA-receptor antagonist, is an orally active diphenyl pr...
متن کامل